Merck gets cancer drug bar as Halozyme wins cross-border European injunction
A Dutch court has barred Merck’s under-the-skin version of cancer drug Keytruda in eight European countries, upholding Halozyme’s drug-delivery patent and applying EU top court guidance allowing courts to issue cross-border...To view the full article, register now.
Already a subscriber? Click here to view full article